Performance guarenteed'


DR4 Monoclonal Antibody (DR-4-02), FITC

Product Details

| Size | 100 µg | | |
|----------------------------|--|--|--|
| Species Reactivity | Human | | |
| Published Species | Human | | |
| Host/Isotype | Mouse / IgG1 | | |
| Class | Monoclonal | | |
| Туре | Antibody | | |
| Clone | DR-4-02 | | |
| Conjugate | FITC | | |
| Excitation/Emission Max | 498/517 nm | | |
| Immunogen | Fusion protein containing the extracellular part of TRAIL-R1 and the constant part of the heavy chain of the human IgG1. | | |
| Form | Liquid | | |
| Concentration | 0.1 mg/mL | | |
| Purification | Size-exclusion chromatography | | |
| Storage buffer | PBS, pH 7.4, with 0.2% BSA | | |
| Contains | 15mM sodium azide | | |
| Storage conditions | 4° C, store in dark, DO NOT FREEZE! | | |
| RRID | AB_1955203 | | |
| | | | |

| Applications | Tested Dilution | Publications |
|-----------------------|-----------------|---------------|
| Flow Cytometry (Flow) | 3-5 µg/mL | 1 Publication |

Product Images For DR4 Monoclonal Antibody (DR-4-02), FITC



DR4 Antibody (MA1-19757) in Flow

Flow cytometry analysis (surface staining) of CD261-transfected HEK-293 cells with anti-CD261/TRAIL-R1 (DR-4-02) FITC Monoclonal antibody (Product # MA1-19757).

1

□1 Reference

Flow Cytometry (1)

eLife

Oxaliplatin resistance in colorectal cancer enhances TRAIL sensitivity via death receptor 4 upregulation and lipid raft localization.

"MA1-19757 was used in Flow Cytometry to examine whether surviving oxaliplatin-resistant subpopulations of cancer cells have an enhanced sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and elucidate mechanisms that drive this sensitization."

Authors: Greenlee JD,Lopez-Cavestany M,Ortiz-Otero N,Liu K,Subramanian T,Cagir B,King MR

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Product is warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample furnished. To super item VED, RATES OR INPERION IS LIMITED TO REPARI, REPLACE OR METCHANTABILITY, FITNESS FOR ANY PARTICLAR PURPOSE, OR NON INFRINGEMENT. BUYER'S SCI.USV ENEMBED'S ALL PURPOSE, OR NON INFRINGEMENT. THE RESTOR TANY PARTICLAR ULTROPES, EXPERSES OR INFRINGENCE OR REFLIND FOR THE NON-CONFORMING PRODUCTS SOLE OPTION. THERE IS NO BILLEDATION TO REFERRE. REPLACE OR REFLIND FOR THE NON-CONFORMING PRODUCTS SOLE OPTION. THERE IS NO BILLEDATION TO REFLIX CO REGULERNEE OF OR BY BUYER'S SCI.USV ENTIONES SOLE OPTION. THERE IS NO BULEDATION TO REFLIX REPLACE OR REFLIX DE NO BULEDATION TO REFLIX REPLACE OR REFLIX DE NO BULEDATION TO REFLIX REPLACE OR REFLIX DE SUCCES SOLE OPTION. THERE IS NO BULEDATION TO REFLIX REPLACE OR REFLIX DE SUCCES SOLE OPTION. THERE IS NO BULEDATION TO REFLIX REPLACE OR REFLIX DE SUCCES SOLE OPTION. THERE IS NO BULEDATION TO REFLIX REPLACE OR REFLIX DE SUCCES SOLE OPTION. THERE IS NO BULEDATION TO REFLIX REPLACE OR REFLIX DE SUCC

Year 2021

> Species Human

2